The Effects of Polaprezinc Combined With AR-inhibitors on Patients With CRPC
Status:
Enrolling by invitation
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the therapy effects and clinical safety of a gastric
ulcer, polaprezinc (POL) with a marketed AR-inhibitors, abiraterone, enzalutamide, or
darolutamimde in Chinese patients with castration-resistant prostate cancer (CRPC).